Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)

NCT03840005 is registered in ClinicalTrials.gov with Sheffield Teaching Hospitals NHS Foundation Trust as lead sponsor.

NCT NCT03840005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03840005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)
Lead sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Phase
Phase 2
Overall status
Completed
Start date
December 18, 2018
Completion date
May 13, 2021
Enrollment
31 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease